

Thomas Jefferson University Jefferson Digital Commons

Department of Family & Community Medicine Presentations and Grand Rounds

Department of Family & Community Medicine

7-16-2020

Review of Treatment Options for Pneumonia in the Inpatient Setting

Shirley B Bonanni Thomas Jefferson University

Follow this and additional works at: https://jdc.jefferson.edu/fmlectures

Part of the Family Medicine Commons, and the Primary Care Commons
<u>Let us know how access to this document benefits you</u>

Recommended Citation

Bonanni, Shirley B, "Review of Treatment Options for Pneumonia in the Inpatient Setting" (2020). *Department of Family & Community Medicine Presentations and Grand Rounds.* Paper 424. https://jdc.jefferson.edu/fmlectures/424

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Family & Community Medicine Presentations and Grand Rounds by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Review of Treatment Options for Pneumonia in the Inpatient Setting

Shirley Bonanni, Pharm.D., BCPS Advanced Practice Pharmacist, Family Medicine Pharmacy Residency Program Director, PGY1 Thomas Jefferson University Hospital 7/16/2020

Pneumonia

- Community acquired pneumonia (CAP)
- Healthcare associated pneumonia (HCAP)
- Hospital-acquired pneumonia (HAP)
- Ventilator associated pneumonia (VAP)
- Aspiration pneumonia

AMERICAN THORACIC SOCIETY DOCUMENTS

Diagnosis and Treatment of Adults with Community-acquired Pneumonia

An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America

Joshua P. Metlay*, Grant W. Waterer*, Ann C. Long, Antonio Anzueto, Jan Brozek, Kristina Crothers, Laura A. Cooley, Nathan C. Dean, Michael J. Fine, Scott A. Flanders, Marie R. Griffin, Mark L. Metersky, Daniel M. Musher, Marcos I. Restrepo, and Cynthia G. Whitney; on behalf of the American Thoracic Society and Infectious Diseases Society of America

This official clinical practice guideline was approved by the American Thoracic Society May 2019 and the Infectious Diseases Society of America August 2019

Metlay JP, et al. Am J Respir Crit Care Med. 2019;200(7):e45-e67

 Table 2. Differences between the 2019 and 2007 American Thoracic Society/Infectious Diseases Society of America

 Community-acquired Pneumonia Guidelines

Recommendation	2007 ATS/IDSA Guideline	2019 ATS/IDSA Guideline
Sputum culture	Primarily recommended in patients with severe disease	Now recommended in patients with severe disease as well as in all inpatients empirically treated for MRSA or <i>Pseudomonas aeruginosa</i>
Blood culture	Primarily recommended in patients with severe disease	Now recommended in patients with severe disease as well as in all inpatients empirically treated for MRSA or <i>P.</i> <i>aeruginosa</i>
Macrolide monotherapy	Strong recommendation for outpatients	Conditional recommendation for outpatients based on resistance levels
Use of procalcitonin	Not covered	Not recommended to determine need for initial antibacterial therapy
Use of corticosteroids	Not covered	Recommended not to use. May be considered in patients with refractory septic shock
Use of healthcare-associated pneumonia category	Accepted as introduced in the 2005 ATS/IDSA hospital-acquired and ventilator-associated pneumonia guidelines	Recommend abandoning this categorization. Emphasis on local epidemiology and validated risk factors to determine need for MRSA or <i>P. aeruginosa</i> coverage. Increased emphasis on deescalation of treatment if cultures are negative
Standard empiric therapy for severe CAP	β-Lactam/macrolide and β-lactam/fluoroquinolone combinations given equal weighting	Both accepted but stronger evidence in favor of β-lactam/macrolide combination
Routine use of follow-up chest imaging	Not addressed	Recommended not to obtain. Patients may be eligible for lung cancer screening, which should be performed as clinically indicated

Definition of abbreviations: ATS = American Thoracic Society; CAP = community-acquired pneumonia; IDSA = Infectious Diseases Society of America; MRSA = methicillin-resistant Staphylococcus aureus.

Metlay JP, et al. Am J Respir Crit Care Med. 2019;200(7):e45-e67

TJUH Antimicrobial Guidelines

- Confluence
 - <u>https://confluence.jefferson.edu/</u>
 - Antimicrobial Stewardship

Community Acquired Pneumonia (CAP)

- Occurs within 48 hours of hospital admission
- Severe CAP

Patients with 1 major or ≥3 minor criteria

Major Criteria	Minor Criteria
 Septic shock with need for vasopressors Respiratory failure requiring mechanical ventilation 	 Respiratory rate ≥ 30 breaths/min PaO₂/FiO₂ ratio ≤ 250 Multilobar infiltrates Confusion/disorientation Uremia (BUN ≥20mg/dl) Leukopenia (WBC <4,000 cells/µl Thrombocytopenia (plt <100,000/µl) Hypothermia (<36°C or <96.8°F) Hypotension requiring aggressive fluid resuscitation

Community Acquired Pneumonia

Major bacterial causes	САР
	Streptococcus pneumoniae
	Haemophilus influenza
	Mycoplasma pneumoniae
	Staphylococcus aureus
	Legionella spp
	Chlamydia pneumonia
	Moraxella catarrhalis

Routine Diagnostic Work-up

- History and Physical Exam
- Vital signs
- Pulse oximetry and/or ABG
- Chest x-ray (PA and lateral)
- CBC with differential
- Basic metabolic panel
- Sputum and blood cultures
- Procalcitonin is <u>not</u> recommended in adults with clinically suspected and radiographically confirmed pneumonia
- Other diagnostics may be required in the appropriate clinical setting (travelers, immunocompromised patients, HIV infection, etc.)

Additional Considerations

	Nonsevere CAP	Severe CAP	НАР	VAP
Sputum for Gram's stain and culture	 Optional but recommended if: Empirically treating MRSA or <i>Pseudomonas</i> Prior respiratory isolation of MRSA or <i>Pseudomonas</i> Recent hospitalization and IV antibiotics within the last 90 days 	Yes	Yes	Yes
Blood cultures x 2	 Optional but recommended if: Empirically treating MRSA or <i>Pseudomonas</i> Prior respiratory isolation of MRSA or <i>Pseudomonas</i> Recent hospitalization and IV antibiotics within the last 90 days 	Yes	Yes	Yes
MRSA nasal screen	 Optional but recommended if: Empirically treating MRSA Prior respiratory isolation of MRSA Recent hospitalization and IV antibiotics within the last 90 days 	 Optional but recommended if: Empirically treating MRSA Prior respiratory isolation of MRSA Recent hospitalization and IV antibiotics within the last 90 days 	Yes	Yes
Streptococcus pneumonia urinary antigen	No	Select patients admitted to an ICU	No	No
<i>Legionella</i> urinary antigen and <i>Legionella</i> culture	Only suggested if: Significant clinical concern OR concern for <i>Legionella</i> outbreak	• Yes	Only suggested if: Significant clinical concern OR concern for <i>Legionella</i> outbreak	Only suggested if: Significant clinical concern OR concern for <i>Legionella</i> outbreak
Flu A/B and RSV PCR	During flu season or significant clinical concern			
Respiratory pathogen panel	Concern for viral etiology in patients who are immunocompromised or critically ill			
HIV screen	If clinically indicated			
EKG	If treating with QTc prolonging antibiotic (ie. azithromycin, levofloxacin)			

Community Acquired Pneumonia


- Assess risk factors for community acquired MRSA (ca-MRSA):
 - Recent hospitalization <u>and</u> IV antibiotics within the last 90 days
 - Preceding or concurrent influenza like illness
 - CAP requiring ICU admission
 - Necrotizing or cavitary infiltrates
 - Empyema
 - Previous colonization or infection with MRSA
 - Intravenous drug abuse
 - Immunocompromised patients

Community Acquired Pneumonia

- Assess risk factors for *Pseudomonas aeruginosa*
 - Recent hospitalization <u>AND</u> IV antibiotic use within the past 90 days
 - Immunocompromised patients
 - Structural lung disease (CF, bronchiectasis)
 - Hospitalization for ≥ 2 days within 90 days
 - Residence in a nursing home or extended care facility
 - Home infusion therapy (including antibiotics)
 - Home wound care
 - Family member with multidrug-resistant organisms (MDRO)
 - Chronic hemodialysis (HD) within 30 days

CAP Treatment Algorithm

Community Acquired Pneumonia (CAP)- without MRSA or Pseudomonas Risk factors



CAP Treatment Algorithm

*Additional Treatment to Consider		
	Nonsevere CAP	Severe CAP
Prior respiratory isolation of MRSA	 Add vancomycin Deescalate based on MRSA nasal screen and sputum culture 	 Add vancomycin Deescalate based on MRSA nasal screen and sputum culture
Prior respiratory isolation of <i>Pseudomonas</i> aeruginosa	Add cefepime in place of ceftriaxoneDeescalate based on sputum culture	 Add cefepime in place of ceftriaxone If severe β Lactam allergy add aztreonam Deescalate based on sputum culture
Recent hospitalization or IV antibiotics within the past 90 days	 Withhold MRSA and Pseudomonas coverage Obtain MRSA nasal screen and sputum culture If results are positive, initiate MRSA or <i>Pseudomonas</i> coverage 	 Add vancomycin Add cefepime in place of ceftriaxone Deescalate based on MRSA nasal screen and sputum culture
Flu A/B positive	Add oseltamivir	Add oseltamivir

Community Acquired Pneumonia

- Which antimicrobial regimen would you select for a non-ICU pt suspected to have non-severe CAP?
 - A. Vancomycin and Cefepime
 - B. Meropenem
 - C. Ceftriaxone and Azithromycin
 - D. I order what Shirley tells me to

CAP De-escalation of Therapy

- De-escalation of therapy
 - Based on clinical improvement and culture results
 - For non critically ill patients, transition to oral therapy as soon as possible
 - Pts initially treated with ceftriaxone + azithromycin:
 - Cefuroxime 500 mg po q12hr* +/- azithromycin 500 mg po q24hr
 - Pts initially treated with levofloxacin or PCN allergic:
 - Levofloxacin 750 mg po daily*

*requires renal dosing

https://confluence.jefferson.edu/display/AGS/TJUH+Guidelines+for+Inpatient+Treatment+of+Pneumonia

CAP Duration of Therapy

Organism	Duration of therapy	
Gram-positive		
MSSA	7 days	
MRSA	7 days	
S. pneumoniae	5 days	
Gram-negative		
Enterobactericeae (E. coli, Enterobacter, Serratia, Klebsiella, etc)	7 days	
Pseudomonas	7 days	
Acinetobacter	7 days	
Atypicals		
Legionella, Mycoplasma	7-14 days	
Chlamydia pneumoniae	10-14 days	

CAP Therapy Discontinuation

- Discontinue abx if:
 - Afebrile for 48-72 hrs <u>AND</u> has no more than 1 of the following:
 - HR > 100 beats/min
 - RR > 24 breaths/min
 - BP < 90 mm Hg
 - O2 sat < 90%
 - Altered mental status
 - Cough and CXR abnormalities can take several weeks to improve
 - No need to extend duration if clinically well



Fluoroquinolone (FQ) Safety

- FDA warnings and precautions
 - Increased risk of tendonitis and tendon rupture
 - Risk of worsening symptoms for those with myasthenia gravis
 - Potential for irreversible peripheral neuropathy
 - Increase in mental health adverse effects and blood glucose disturbances
 - Increased risk of aneurysm and dissection
 - C.difficile

https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020634s070lbl.pdf#page=52

Hospital-Acquired Pneumonia (HAP)

- Pneumonia that occurs ≥ 48 hours after admission
- Not incubating at the time of admission
- Also referred to as nosocomial pneumonia


HAP Suspected Organisms

Nosocomial Pneumonia*
Escherichia coli
Klebsiella pneumoniae
Enterobacter spp
Pseudomonas aeruginosa
Acinetobacter spp
Staphylococcus aureus including MRSA
Streptococcus spp

*HAP and VAP may be caused by a wide variety of pathogens, can be polymicrobial, and depends in large part upon whether the patient has risk factors for MDR pathogens. Differences in patient factors and the hospital flora also influence the patterns of pathogens seen.

HAP Treatment Algorithm

Hospital Acquired Pneumonia (HAP)



HAP Treatment Algorithm

- Double coverage for gram-negative organisms
 - Patients who have received prior intravenous antibiotics within the preceding 90 days
 - Structural lung disease (ie. bronchiectasis, CF)
- At risk for multidrug-resistant (MDR) gramnegative pathogens, including *pseudomonas*, should receive <u>2 different agents</u> with gramnegative activity

Additional Considerations

	Nonsevere CAP	Severe CAP	НАР	VAP
Sputum for Gram's stain and culture	 Optional but recommended if: Empirically treating MRSA or <i>Pseudomonas</i> Prior respiratory isolation of MRSA or <i>Pseudomonas</i> Recent hospitalization and IV antibiotics within the last 90 days 	Yes	Yes	Yes
Blood cultures x 2	 Optional but recommended if: Empirically treating MRSA or <i>Pseudomonas</i> Prior respiratory isolation of MRSA or <i>Pseudomonas</i> Recent hospitalization and IV antibiotics within the last 90 days 	Yes	Yes	Yes
MRSA nasal screen	 Optional but recommended if: Empirically treating MRSA Prior respiratory isolation of MRSA Recent hospitalization and IV antibiotics within the last 90 days 	 Optional but recommended if: Empirically treating MRSA Prior respiratory isolation of MRSA Recent hospitalization and IV antibiotics within the last 90 days 	Yes	Yes
Streptococcus pneumonia urinary antigen	No	 Select patients admitted to an ICU 	No	No
<i>Legionella</i> urinary antigen and <i>Legionella</i> culture	Only suggested if: Significant clinical concern OR concern for <i>Legionella</i> outbreak	• Yes	Only suggested if: Significant clinical concern OR concern for <i>Legionella</i> outbreak	Only suggested if: Significant clinical concern OR concern for <i>Legionella</i> outbreak
Flu A/B and RSV PCR	During flu season or significant clinical concern			
Respiratory pathogen panel	Concern for viral etiology in patients who are immunocompromised or critically ill			
HIV screen	If clinically indicated			
EKG	If treating with QTc prolonging antibiotic (ie. azithromycin, levofloxacin)			

HAP De-escalation of Therapy

- Deescalate based on clinical improvement and culture results.
 - For non-critically ill patients, transition to oral therapy as soon as possible.
- Culture–negative step down therapy:
 - Obtain MRSA nasal swab upon admission.
 - If no MRSA isolated and nasal screen negative, consider discontinuation of vancomycin after 48hrs
- If no culture data available and the patient is improving, you can deescalate to levofloxacin 750mg PO q24h

HAP Duration of Therapy

• 7 days!

https://confluence.jefferson.edu/display/AGS/TJUH+Guidelines+for+Inpatient+Treatment+of+Pneumonia

HAP Therapy Discontinuation

- Discontinue antibiotics if:
 - Patient is afebrile for 48-72hours AND has no more than 1 of the following:
 - HR >100 beats/min
 - RR >24 breaths/min
 - BP < 90mmg Hg
 - O2 Sat < 90%
 - Altered Mental Status
 - Cough and CXR abnormalities can take several weeks to improve
 - No need to extend duration if clinically well

Active surveillance cultures of methicillin-resistant *Staphylococcus aureus* as a tool to predict methicillin-resistant *S. aureus* ventilator-associated pneumonia*

Jeannie D. Chan, PharmD, MPH; Timothy H. Dellit, MD; Julie A. Choudhuri, RN, MSPH; Elizabeth McNamara, RN, MN; Elizabeth J. Melius, RN, MN, MPH; Heather L. Evans, MD, MS; Joseph Cuschieri, MD; Saman Arbabi, MD, MPH; John B. Lynch, MD, MPH

Chan JD, Dellit TH, Choudhuri JA, et al. Active surveillance cultures of methicillin-resistant Staphylococcus aureus as a tool to predict methicillin-resistant S. aureus ventilator-associated pneumonia. *Crit Care Med*. 2012;40(5):1437-1442. doi:10.1097/CCM.0b013e318243168e

- Prospective observational study conducted at a university-affiliated urban teaching hospital
- VAP patients ≥ 16 years old
 - 924 episodes of suspected VAP evaluated with bronchoscopy
 - 393 pts had microbiologically confirmed VAP
 - 5 excluded due to <16 yrs or screen not performed
 - 54 patients were colonized with MRSA by ASC

• Common sites: nares, posterior oropharynx, trachea

Chan JD, Dellit TH, Choudhuri JA, et al. Active surveillance cultures of methicillin-resistant Staphylococcus aureus as a tool to predict methicillin-resistant S. aureus ventilator-associated pneumonia. *Crit Care Med*. 2012;40(5):1437-1442. doi:10.1097/CCM.0b013e318243168e

- Sensitivity 70.3% (95% Cl, 52.8-83.6)
- Specificity 92% (95% Cl, 88.5-94.5)
- Positive predictive value 48.1% (95% Cl, 34.5-62)
- Negative predictive value <u>96.7%</u> (95% CI, 94-98.3)

Chan JD, Dellit TH, Choudhuri JA, et al. Active surveillance cultures of methicillin-resistant Staphylococcus aureus as a tool to predict methicillin-resistant S. aureus ventilator-associated pneumonia. *Crit Care Med*. 2012;40(5):1437-1442. doi:10.1097/CCM.0b013e318243168e

- High negative predictive value
 - Indicates that negative screens are very accurate for excluding MRSA as a cause of pneumonia

- Aspiration inhalation of oropharyngeal or gastric contents into larynx and lower respiratory tract
 - Contents may include:
 - Different substances (blood, vomitus, food particles)
 - Oropharyngeal secretions
 - Microbiological flora

Waybright, RA et al. Treatment of clinical aspiration: A reappraisal. Am J Health-Syst Pharm – Vol 70 Aug 1 2013; 1291-1300.

- Complications of aspiration:
 - Chemical pneumonitis
 - Damage of lung parenchyma after inhalation of sterile stomach or oropharyngeal contents into lower airway
 - Due to gastric acid and delayed inflammatory reaction
 - Non-infectious process
 - Aspiration pneumonia
 - Infectious process
 - Occurs after inhalation of colonized pathogenic bacteria into lower airway from oropharyngeal area or colonized gastric contents
 - Often occurs silently

Waybright, RA et al. Treatment of clinical aspiration: A reappraisal. Am J Health-Syst Pharm – Vol 70 Aug 1 2013; 1291-1300.

- Despite distinct physiological processes, clinical presentation can be difficult to distinguish
- Bacteriology
 - Associated microbial spectrum included gram positive (S. aureus, S. pneumoniae), gram negative (H. influenzae, enterobacteriaceae), and anaerobes (bacteroides, peptostreptococcus, fusobacterium)
 - From studies from the 1970s


Waybright, RA et al. Treatment of clinical aspiration: A reappraisal. Am J Health-Syst Pharm – Vol 70 Aug 1 2013; 1291-1300.

- Broader spectrum antibiotics not necessarily more effective
- Potential abx choice should target nonresistant gram positive (*Staphylococcus* and *Streptococcus* species) and gram negative (Enterobacteriaceae, *H. influenzae*)

 Pneumonia (fever, cough, infiltrate) that develops 48 – 72 hrs after suspected or witnessed aspiration event

Question

- In aspiration pneumonia, should you cover for anaerobes?
 - Yes
 - No



https://confluence.jefferson.edu/display/AGS/TJUH+Guidelines+for+Inpatient+Treatment+of+Pneumonia

- Assess for risk factors for anaerobic infection:
 - Loss of consciousness due to alcoholism
 - Seizures
 - Gingival disease
 - Esophageal motility issues
 - Lung abscess
 - Empyema

https://confluence.jefferson.edu/display/AGS/TJUH+Guidelines+for+Inpatient+Treatment+of+Pneumonia

- De-escalation of therapy
 - Culture negative step down therapy:
 - Amoxicillin/clavulanate (Augmentin) 875 mg po q12hr
 OR
 - Levofloxacin 750 mg po q24hr +/- metronidazole
 OR
 - Cefuroxime 500 mg po q12hr (if anaerobic coverage not required)
- Reassess patients in 48-72 hrs, if no symptoms or confirmatory cx or imaging, likely chemical pneumonitis and can discontinue abx

Antimicrobial Dosing

Antimicrobial	Recommended Dosing
Amoxicillin/ Clavulanate	875mg po q12h
Ampicillin/Sulbactam	1.5gm iv q6h
Azithromycin	500mg iv/po q24h
Aztreonam	1gm iv q8h
Amikacin	CrCl > 20ml/min: 15mg/kg iv (dosing interval based on renal function)
Cefepime	CrCl ≥ 60ml/min: 2000mg iv q8h given as a 3hr infusion
Ceftriaxone	1gm iv q24h
Cefuroxime	500mg po q12h
Clindamycin	600mg iv/po q8h
Doxycycline	100mg iv/po q12h
Levofloxacin	750 mg iv/po q24h
Linezolid	600mg iv/po q12h
Meropenem	CrCl > 50ml/min: 1-2gm iv q8h given as a 3hr infusion
Metronidazole	500mg iv/po q12h
Oseltamivir	75mg PO twice daily
Tobramycin	CrCl >20ml/min: 6 mg/kg iv (dosing interval based on renal function)
Vancomycin	Loading dose 25mg/kg rounded to nearest 500mg; consult pharmacy or intranet guidelines for maintenance dosing

https://confluence.jefferson.edu/display/AGS/TJUH+Guidelines+for+Inpatient+Treatment+of+Pneumonia

Wrap-up

- De-escalate when appropriate
 - Prolonged use of broad spectrum abx can lead to:
 - Resistance
 - C. diff infections
- Longer duration does not equal better outcomes!

Questions?